CI

Business Context and Reporting Period

Company: The Cigna Group
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2024
Business Overview: A global health company operating through two primary reportable segments: Evernorth Health Services (pharmacy and specialty care) and Cigna Healthcare (medical and coordinated solutions). The Company is a large accelerated filer.

Key Financial Metrics

Note: Debt figures include short-term debt ($2,572M) and long-term debt ($30,230M) as of September 30, 2024.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 30% in Q3 and 26% year-to-date (YTD), driven primarily by a 40% increase in Pharmacy revenues due to higher utilization and customer growth in Evernorth Health Services.
• Net Income Decline: Shareholders' net income decreased 48% in Q3 and 51% YTD. This decline is primarily attributable to a $2.7 billion impairment loss on equity securities (VillageMD) and a $182 million impairment of dividend receivable, which are excluded from Adjusted Income from Operations.
• Adjusted Performance: Excluding special items, Adjusted Income from Operations increased 5% in Q3 and 8% YTD, reflecting underlying operational strength in Evernorth and Cigna Healthcare.
• Investment Losses: Net realized investment losses were $921 million in Q3 and $2.8 billion YTD, compared to $14 million and $44 million in the prior year periods, respectively.
• Effective Tax Rate: The effective tax rate increased to 30.8% (Q3) and 31.2% (YTD) from 21.3% and 19.9% in the prior year, driven by a valuation allowance established on tax benefits related to the equity impairment.

Guidance, Outlook, and Risks

• Divestiture: The Company entered a definitive agreement in January 2024 to sell its Medicare Advantage and related businesses to Health Care Service Corporation (HCSC) for approximately $3.3 billion cash. The transaction is expected to close in Q1 2025. Proceeds are anticipated to be used primarily for share repurchases.
• Capital Allocation: The Company repurchased approximately $5.0 billion of common stock in the first nine months of 2024, including $3.2 billion via Accelerated Share Repurchase (ASR) agreements. As of October 30, 2024, $5.6 billion of repurchase authority remains.
• Dividends: The Board declared a quarterly dividend of $1.40 per share for Q4 2024, payable in December 2024.
• Medicare Star Ratings: The Company estimates 69% of its Medicare Advantage customers are in plans eligible for quality bonus payments for 2025 and 2026.
• Risks: Key risks include the outcome of the ongoing litigation with Elevance Health (pricing claims appeal), potential credit deterioration in the commercial mortgage loan portfolio (specifically office sector exposure), and regulatory changes affecting Medicare Advantage rates.

Investor Verification Checklist

• Impairment Details: Verify the specific accounting treatment and future tax implications of the $2.7 billion VillageMD equity impairment and the $182 million dividend receivable impairment.
• HCSC Transaction Timeline: Monitor regulatory approval status and the expected Q1 2025 closing date for the Medicare Advantage divestiture.
• Pharmacy Margin Trends: Review Evernorth Health Services' pre-tax adjusted margin, which decreased 80 basis points in Q3 to 3.6%, to understand the impact of drug inflation and affordability services.
• Debt Maturity Profile: Assess the impact of rising interest rates on the $32.8 billion total debt load, noting the Company's use of interest rate swaps to hedge a portion of fixed-rate debt.
• Legal Proceedings: Track the status of the Elevance Health litigation appeal, as an adverse outcome could be material to future results.